Prior Authorization Form



Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Presci	riber Information	
Patient Name:		Prescriber Name:		
Health Plan Name:		Prescriber Address:		
Patient Insurance Id:		-		
Patient Date of Birth:		Prescriber Phone:	()	
Patient Phone:		Prescriber Fax:	()	
-		Prescriber Specialty:		
		Prescriber DEA:		
		Prescriber NPI:		
Medica	tion & Me	edical Information		
Requested Drug(s) & Strength(s):	[] Vumer	rity 231 mg capsule,delayed re	lease	
Requested Daily Quantity Limit – Amount:				
Requested Daily Quantity Limit – Days:				
Expected Length of Therapy:				
Directions:				
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):				
List drugs used previously to treat the same condition:				
Additional clinical information or history. Please include any relevant test results and/or medical record notes:				
Questionnaire				
Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply) [] Yes				
[] No				
Q2: Is the requested medication used in combination				
[] Yes (please provide clinical rationale for the re (*Required) $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	equest)			
[] No				
Q3: Is the member currently treated with this medication? (Check only one that apply)				

Prior Authorization Form



[] Yes (please list start date of therapy (month/day/year))(*Required)	
[] No	
Q4: What is the member's diagnosis? (Check only one that apply)	
[] Relapsing form of MS (e.g., clinically isolated syndrome, relapsing-remitting disease, including active disease with new brain lesions) (please specify) (*Required)	
[] Other (please specify the member's diagnosis and provide clinical rationale for the re(*Required)	equest)
Q5: Does the member have documentation of positive clinical response to therapy (e.g., state clinical relapses, disease progression)? (Check only one that apply)	oility in radiologic disease activity,
[] Yes (please provide the supporting documents)(*Required)	
[] No (please provide medical justification for continuation of therapy)(*Required)	
Q6: What is the member's diagnosis? (Check only one that apply)	
[] Relapsing form of MS (e.g., clinically isolated syndrome, relapsing-remitting disease, including active disease with new brain lesions) (please specify)	secondary progressive disease,
[] Other (please specify the member's diagnosis and provide clinical rationale for the re(*Required)	equest)
Q7: Has the member had an inadequate response, intolerance or experienced contraindicati the following disease-modifying therapies for MS: Aubagio (teriflunomide), Gilenya (fingolim dimethyl fumarate? (Check only one that apply)	
[] Yes (please specify drug name(s), corresponding contraindication(s) or intolerance ex (s) of therapy (month/year))	
[] No	
Q8: Is the member on continuation of prior therapy? (Check only one that apply)	
[] Yes	
[] No (please provide clinical rationale for the request)(*Required)	
Q9: Is the requusted medication prescribed by or in consultation with a neurologist? (Check	only one that apply)
[] Yes(*Required)	
[] No (please provide clinical rationale for the request)(*Required)	
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I unde Medical Group or its designated representatives may perform a routine audit and request the medical accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	